findmyKOL
Clinical trialNCT03707977CompletedPhase 1/PHASE2Interventional

Dual bNAb Treatment in Children

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment30HIV Infection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the impact of two broadly neutralizing antibodies, VRC01LS and 10-1074, on the maintenance of HIV suppression in a cohort of early-treated children in Botswana.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Botswana
  • Francistown Non-Network Crs

    Francistown, Botswana

  • Botswana Harvard Aids Institute Partnership Crs Non-Network

    Gaborone, Botswana

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

10-1074ARTVRC01LS
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Jun 2019
Primary completion
3 Dec 2021
Completion
3 Dec 2021
Last update posted
4 May 2026
Registered enrollment
30
Registry id
NCT03707977
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.